Special Issue

Emerging Viruses and Antiviral Drugs, 2nd Edition

Message from the Guest Editors

Emerging viruses are a very broad category that includes not only newly discovered viruses but also reemerging variants of known viruses. These viruses continue to cause mass disruption by creating constant threat to public health. In the last 20 years, we have observed a variety of viral outbreaks, such as severe acute respiratory symptom (SARS), H1N1 influenza, Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), Rift Valley fever, Crimean Congo hemorrhagic fever, Nipah and Hendra viruses, severe fever with thrombocytopenia syndrome virus (SFTSV), vellow fever virus (YFV), Zika virus, and the ongoing SARS-CoV-2. The globalization of the economies and quick-paced traveling patterns of human populations, combined with climate change, are creating ample opportunities for mass spread of viral infections. This Special Issue, "Emerging Viruses and Antiviral Drugs". focuses on various antiviral approaches to manage emerging and re-emerging viruses and will include antiviral drug discovery, discovery of the mechanism of actions, new targets, and upcoming and established technologies used for discovery and development of antiviral drugs.

Guest Editors

Dr. Veronica Soloveva

Department of Quantitative Biosciences, Merck, Boston, MA, USA

Dr. Miguel A. Martín-Acebes

Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), 28040 Madrid, Spain

Dr. Sina Bavari

CSO, Co-founder of Healion Bio, Frederick, MD, USA

Deadline for manuscript submissions

closed (31 March 2025)



Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/185180

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/ microorganisms





Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

